Europe—not US—first to authorize Moderna’s combo mRNA flu-COVID vaccine

This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...

Moderna starts late-stage trial for bird flu vaccine

Moderna (MRNA) announced on Wednesday that the company has initiated dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu vaccine candidate, mRNA-1018, in the U.S. and U.K.
European Medical Journal

Moderna initiates phase 3 bird flu vaccine trial

A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...